Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloablative haploidentical HSCT with post‑transplant cyclophosphamide for refractory hematological malignancies
jRCTs051180118Recruiting
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cyclophosphamide in hematopoietic malignancies. Primary endpoint: One-year survival rate following transplantation. Started Sep 2017; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on jRCTs051180118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180118.